Trial Profile
MAVERICC (Marker Evaluation for Avastin Research in CRC): A Randomized Phase II Study of Bevacizumab+mFOLFOX6 Vs. Bevacizumab+FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Biomarker; Therapeutic Use
- Acronyms MAVERICC
- Sponsors Genentech
- 20 Jan 2024 Results of pooled analysis from TRIBE , FIRE-3 and MAVERICC ; investigating the effect of myostatin/activin pathway gene expression and SNPs in mCRC patients, presented at the 2024 Gastrointestinal Cancers Symposium
- 06 Jun 2023 Results assessing the effect of genetic variants in MHC class I and II pathways on first-line treatment outcome in mCRC patients presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 22 Jan 2022 Data from MAVERICC and TRIBE trials assessing genetic variants in the ferroptosis regulator genes may predict first-line treatment outcome in RAS-mutant mCRC pts treated with bevacizumab (bev)-based chemotherapy presented at the 2022 Gastrointestinal Cancers Symposium